NCT05991232View on ClinicalTrials.gov

Repeated Neurocognitive Measurements in Depressed Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Depression, Unipolar
Interventions
DRUG

Intravenous Ketamine

Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)

Sponsors

Lead Sponsor

Jay Fournier
All Listed Sponsors
lead

Jay Fournier

OTHER

NCT05991232 - Repeated Neurocognitive Measurements in Depressed Patients | Biotech Hunter | Biotech Hunter